Pier Capital LLC Boosts Investment in Intra-Cellular Therapies, for 2023.

Trending News ☀️

Pier Capital LLC has recently made a substantial investment in Intra-Cellular Therapies, Inc. for the year 2023. This move marks an increase in Pier Capital LLC’s ownership of the company, and it signals an increased focus on this cutting-edge type of therapy. Intra-Cellular Therapies, Inc. specializes in providing therapies that target the inner workings of cells, offering treatments for a wide range of diseases and conditions. This type of therapy has been gaining traction in recent years and is showing great promise for the future. Intra-cellular ($NASDAQ:ITCI) therapy focuses on improving the function of cells within the body. By targeting the inner workings of cells, these therapies have the potential to restore health and prevent disease progression.

These treatments can be used to treat a variety of conditions, including neurological disorders, cancer, autoimmune diseases, and more. With this increased investment, Intra-Cellular Therapies, Inc. will be able to expand their research capabilities and further develop their treatments. By expanding their research capabilities and continuing to develop their therapies, they are working towards a better future for those who need these treatments. This move demonstrates Pier Capital LLC’s commitment to innovation and progress in the field of intra-cellular therapies. With this increased investment in Intra-Cellular Therapies, Inc., patients around the world may soon benefit from these revolutionary treatments.

Share Price

This news caused a surge in the stock price of INTRA-CELLULAR THERAPIES as it opened at $43.8 and closed at $45.1, up by 2.5% from its previous closing price of $44.0. This rise in the stock price indicates that investors have faith in Intra-Cellular Therapies‘ therapeutic approaches and its promising prospects in the future. Intra-Cellular Therapies focuses on developing therapies that are targeted at issues found in the cells, such as neuropsychiatric disorders, cancer, and other neurological diseases. The increase in investment by Pier Capital LLC is likely to help accelerate Intra-Cellular Therapies’ research and development projects, and bring new treatments to the market faster. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Intra-cellular Therapies. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Intra-cellular Therapies. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Intra-cellular Therapies. More…

Key Ratios Snapshot

Some of the financial key ratios for Intra-cellular Therapies are shown below. More…

Analysis

At GoodWhale, we have conducted an extensive analysis of INTRA-CELLULAR THERAPIES‘s wellbeing. Our Risk Rating has indicated that INTRA-CELLULAR THERAPIES is a high risk investment in terms of both financial and business aspects. We have detected four risk warnings across the balance sheet, cashflow statement, non-financial, and financial journals. Our team has worked hard to identify these potential risks and provide insight on how to mitigate them. If you are considering investing in INTRA-CELLULAR THERAPIES, we highly recommend that you register with us to gain access to our full report. Our report will provide you with an in-depth understanding of the risks associated with this investment and give you the confidence to make an informed decision. More…

Peers

The company’s lead product candidate, lumateperone, is in Phase III clinical trials for the treatment of schizophrenia. SCYNEXIS Inc, Invion Ltd, and Shuttle Pharmaceuticals Holdings Inc are all clinical stage biopharmaceutical companies that focus on the development of small molecule drugs for the treatment of neuropsychiatric disorders.

– SCYNEXIS Inc ($NASDAQ:SCYX)

SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of oral and intravenous anti-infective agents to treat patients with serious and life-threatening infections. The company’s lead product, SCY-078, is a novel, first-in-class oral and intravenous agent in clinical development for the treatment of serious fungal infections. The company’s second product, SCY-123, is an oral agent in clinical development for the treatment of bacterial infections, including Clostridium difficile infection.

– Invion Ltd ($ASX:IVX)

Invion Ltd is a development stage biopharmaceutical company, which focuses on the treatment of cancer and inflammatory disease. The company was founded in 2003 and is headquartered in Brisbane, Australia.

– Shuttle Pharmaceuticals Holdings Inc ($NASDAQ:SHPH)

Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company with a market cap of 25.81M as of 2022. The company has a Return on Equity of 47.66%. Shuttle Pharmaceuticals Holdings Inc is engaged in the research, development, manufacture, and sale of pharmaceutical products. The company’s products include prescription and over-the-counter drugs, as well as nutritional supplements and other health-related products.

Summary

Intra-Cellular Therapies, Inc. (ICT) has received a boost in investments from Pier Capital LLC for 2023. ICT is a biopharmaceutical company committed to the development of novel drugs to address unmet medical needs in neuropsychiatric and other diseases. Analysts believe that ICT has potential due to its focus on innovative therapies and its progress in developing clinical candidates. They believe the company has a strong pipeline of products and attractive partnerships with large corporations, which could enable the company to capture market share.

In addition, the recent investment from Pier Capital is seen as a vote of confidence in ICT’s growth prospects. Analysts recommend that investors stay tuned for further updates on the company’s progress.